Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Bioxyne Ltd (BXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C12411)・商品コード:DATA904C12411
・発行会社(調査会社):GlobalData
・発行日:2018年12月
・ページ数:29
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd (BXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Bioxyne Enters into Agreement with Datapharm Australia 10
Equity Offering 11
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Debt Offering 14
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Acquisition 15
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd – Key Competitors 16
Bioxyne Ltd – Key Employees 17
Bioxyne Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 19
Corporate Communications 21
May 01, 2018: Bioxyne: Non-Executive Director Appointment – Peter Charles Hughes-Hallett 21
Feb 15, 2018: Bioxyne: Resignation of Director 22
Product News 23
Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 23
Other Significant Developments 24
Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 24
Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 25
Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 26
Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 27
Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Bioxyne Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Bioxyne Enters into Agreement with Datapharm Australia 10
Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11
Bioxyne to Raise Funds through Private Placement of Shares 12
Bioxyne Completes Private Placement Of Shares For US$0.5 Million 13
Bioxyne Announces Private Placement Of Notes For US$0.5 Million 14
Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For US$1.4 Million 15
Bioxyne Ltd, Key Competitors 16
Bioxyne Ltd, Key Employees 17
Bioxyne Ltd, Subsidiaries 18

List of Figures
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C12411)販売に関する免責事項を必ずご確認ください。
★調査レポート[Bioxyne Ltd (BXN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆